Browsing Tag
Nipocalimab
9 posts
Is Johnson & Johnson quietly building a new autoimmune franchise around FcRn inhibition?
Johnson & Johnson is expanding nipocalimab into multiple autoimmune indications. Find out if FcRn inhibition is the foundation of its next blockbuster franchise.
Could FcRn blockers become the next biologics blockbuster class after interleukin inhibitors and JAKs?
A new frontier is emerging in the world of biologic therapies. After years of dominance by interleukin inhibitors…
Can Johnson & Johnson’s nipocalimab redefine autoimmune treatment by targeting Sjögren’s disease at its root?
Nipocalimab showed major efficacy in Phase 2 Sjögren’s disease trial. Discover how Johnson & Johnson is advancing autoimmune therapies with its FcRn pipeline.
Johnson & Johnson (NYSE: JNJ) wins key CHMP backing for nipocalimab in gMG—could this reshape Europe’s autoimmune treatment market?
Johnson & Johnson’s nipocalimab wins CHMP backing for gMG, setting stage for potential EU approval in adults and adolescents. Learn what this means for patients.
How does nipocalimab compare to efgartigimod and rozanolixizumab? FcRn class battlelines in gMG and beyond
Compare nipocalimab, efgartigimod, and rozanolixizumab on efficacy, safety, dosing, pricing, and market strategy in generalized myasthenia gravis treatment.
Johnson & Johnson posts sustained superiority for IMAAVY in gMG vs rival FcRn blockers in 24-week indirect comparison
New 24-week comparison shows Johnson & Johnson’s IMAAVY outperforms other FcRn blockers in gMG control—see what this means for patients and investors.
Johnson & Johnson’s nipocalimab meets primary endpoint in Sjögren’s disease trial
Johnson & Johnson (NYSE: JNJ), a global leader in healthcare, announced significant progress in the treatment of Sjögren’s…
Nipocalimab developer Momenta Pharmaceuticals to be acquired by J&J
J&J acquisition of Momenta Pharmaceuticals : US healthcare giant Johnson & Johnson (J&J) has signed a $6.5 billion…
From biosimilars to biotech gold: How Momenta scored a $6.5bn exit with J&J
Johnson & Johnson is acquiring Momenta Pharmaceuticals for $6.5 billion to expand its autoimmune pipeline. Find out what makes nipocalimab worth the bet.